Insider · CIK 0001816836
Matthew Norkunas
Files at GBIO (Generation Bio Co.), OBX (Obsidian Therapeutics, Inc.). First filing -, latest -.
In brief
Matthew Norkunas files SEC Form 4 as CFO and director at GBIO (Generation Bio Co.), and also at OBX (Obsidian Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Matthew Norkunas has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | OBX Obsidian Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +37,653 | $0.00 | $0 | 37,653 | Aug 5, 2026 |
| Oct 15, 2024 | GBIO Generation Bio Co. | MOption exercise Common Stock | +1,674 | - | - | 56,659 | Oct 17, 2024 |
| Oct 15, 2024 | GBIO Generation Bio Co. | FTax withholding Common Stock | -492 | $2.42 | $1,191 | 56,167 | Oct 17, 2024 |
| Oct 15, 2024 | GBIO Generation Bio Co. | MOption exercise Common Stock | +1,673 | - | - | 57,840 | Oct 17, 2024 |
| Oct 15, 2024 | GBIO Generation Bio Co. | FTax withholding Common Stock | -492 | $2.42 | $1,191 | 57,348 | Oct 17, 2024 |
| Oct 15, 2024 | GBIO Generation Bio Co. | MOption exercise Restricted Stock Unitsderivative | -1,674 | $0.00 | $0 | 15,059 | Oct 17, 2024 |
| Oct 15, 2024 | GBIO Generation Bio Co. | MOption exercise Restricted Stock Unitsderivative | -1,673 | $0.00 | $0 | 1,673 | Oct 17, 2024 |
| Dec 1, 2023 | GBIO Generation Bio Co. | AGrant or award Stock Option (right to buy)derivative | +76,310 | $0.00 | $0 | 76,310 | Dec 5, 2023 |
| Oct 15, 2023 | GBIO Generation Bio Co. | MOption exercise Common Stock | +7,437 | - | - | 40,933 | Oct 17, 2023 |
| Oct 15, 2023 | GBIO Generation Bio Co. | FTax withholding Common Stock | -2,183 | $3.24 | $7,073 | 38,750 | Oct 17, 2023 |
| Oct 15, 2023 | GBIO Generation Bio Co. | MOption exercise Common Stock | +1,674 | - | - | 40,424 | Oct 17, 2023 |
| Oct 15, 2023 | GBIO Generation Bio Co. | FTax withholding Common Stock | -492 | $3.24 | $1,594 | 39,932 | Oct 17, 2023 |
| Oct 15, 2023 | GBIO Generation Bio Co. | MOption exercise Restricted Stock Unitsderivative | -7,437 | $0.00 | $0 | 7,437 | Oct 17, 2023 |
| Oct 15, 2023 | GBIO Generation Bio Co. | MOption exercise Restricted Stock Unitsderivative | -1,674 | $0.00 | $0 | 8,366 | Oct 17, 2023 |
Questions about Matthew Norkunas
Answered from the filings on this page, as of the latest one.
Is Matthew Norkunas buying or selling?
Matthew Norkunas has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Matthew Norkunas's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matthew Norkunas has 0.
Where does Matthew Norkunas file Form 4?
Matthew Norkunas has filed Form 4 at GBIO (Generation Bio Co.) as CHIEF FINANCIAL OFFICER; OBX (Obsidian Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.